Skip to main content
. Author manuscript; available in PMC: 2015 Jul 30.
Published in final edited form as: Gene Ther. 2015 Mar 19;22(5):430–438. doi: 10.1038/gt.2015.18

Figure 2. β-cell-targeted PDL1-CTLA4Ig or IL10 expression blocked development of autoimmune diabetes in NOD mice.

Figure 2

A. Female NOD mice were treated with indicated AAV vectors and fasting blood glucose levels were monitored for 16 weeks. Fisher's exact test analysis indicated AAV-IL10 and AAV-PDL1-CTLA4Ig treatments reduced the incidence of spontaneous diabetes (p<0.05). B. Representative pancreatic islets of AAV8 vector-treated or control mice stained with anti-insulin (green) and anti-glucagon (red) antibodies. Nuclei were counterstained with DAPI. C. Islets with infiltrating cells in untreated and AAV-PDL1-CTLA4Ig-treated mice were stained for insulin and CD45 by specific antibodies. D. Insulin-positive beta-cells in whole pancreatic sections were visualized by anti-insulin antibody (representative images from control, AAV-IL10 and AAV-PDL1-CTLA4Ig-treated mice), and percent beta cell areas were compared between the treatments (n=3 each). *p<0.05, Student's t-test.